Literature DB >> 30671625

[Raynaud's phenomenon : Practical management for dermatologists].

Christian Drerup1, Jan Ehrchen2.   

Abstract

Raynaud's phenomenon (RP) is a painful vasospasm of small arteries, localised in fingers and toes. Typically these body parts turn white (ischemia), then blue (deoxygenation) and then red (reperfusion). Two different types of RP exist: the common primary RP without underlying disease and the rare secondary RP, mostly associated with rheumatoid diseases such as systemic sclerosis. Thus, the dermatologist has to be aware of this condition. In this article the clinical criteria, differential diagnoses, diagnostic considerations and treatment options are discussed.

Entities:  

Keywords:  Connective tissue disease; Cyanosis; Ischemia; Nailfold capillaroscopy; Systemic sclerosis

Mesh:

Year:  2019        PMID: 30671625     DOI: 10.1007/s00105-018-4353-9

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  16 in total

Review 1.  Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials.

Authors:  Matthieu Roustit; Sophie Blaise; Yannick Allanore; Patrick H Carpentier; Evren Caglayan; Jean-Luc Cracowski
Journal:  Ann Rheum Dis       Date:  2013-02-20       Impact factor: 19.103

2.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Authors:  M Dziadzio; C P Denton; R Smith; K Howell; A Blann; E Bowers; C M Black
Journal:  Arthritis Rheum       Date:  1999-12

Review 3.  Raynaud's Phenomenon.

Authors:  Fredrick M Wigley; Nicholas A Flavahan
Journal:  N Engl J Med       Date:  2016-08-11       Impact factor: 91.245

Review 4.  ESVM guidelines - the diagnosis and management of Raynaud's phenomenon.

Authors:  Jill Belch; Anita Carlizza; Patrick H Carpentier; Joel Constans; Faisel Khan; Jean-Claude Wautrecht; Adriana Visona; Christian Heiss; Marianne Brodeman; Zsolt Pécsvárady; Karel Roztocil; Mary-Paula Colgan; Dragan Vasic; Anders Gottsäter; Beatrice Amann-Vesti; Ali Chraim; Pavel Poredoš; Dan-Mircea Olinic; Juraj Madaric; Sigrid Nikol; Ariane L Herrick; Muriel Sprynger; Peter Klein-Weigel; Franz Hafner; Daniel Staub; Zan Zeman
Journal:  Vasa       Date:  2017-09-12       Impact factor: 1.961

5.  Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.

Authors:  R Scorza; M Caronni; B Mascagni; V Berruti; S Bazzi; E Micallef; G Arpaia; M Sardina; L Origgi; M Vanoli
Journal:  Clin Exp Rheumatol       Date:  2001 Sep-Oct       Impact factor: 4.473

6.  Update of EULAR recommendations for the treatment of systemic sclerosis.

Authors:  Otylia Kowal-Bielecka; Jaap Fransen; Jerome Avouac; Mike Becker; Agnieszka Kulak; Yannick Allanore; Oliver Distler; Philip Clements; Maurizio Cutolo; Laszlo Czirjak; Nemanja Damjanov; Francesco Del Galdo; Christopher P Denton; Jörg H W Distler; Ivan Foeldvari; Kim Figelstone; Marc Frerix; Daniel E Furst; Serena Guiducci; Nicolas Hunzelmann; Dinesh Khanna; Marco Matucci-Cerinic; Ariane L Herrick; Frank van den Hoogen; Jacob M van Laar; Gabriela Riemekasten; Richard Silver; Vanessa Smith; Alberto Sulli; Ingo Tarner; Alan Tyndall; Joep Welling; Frederic Wigley; Gabriele Valentini; Ulrich A Walker; Francesco Zulian; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2016-11-09       Impact factor: 19.103

7.  Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.

Authors:  Martial Koenig; France Joyal; Marvin J Fritzler; André Roussin; Michal Abrahamowicz; Gilles Boire; Jean-Richard Goulet; Eric Rich; Tamara Grodzicky; Yves Raymond; Jean-Luc Senécal
Journal:  Arthritis Rheum       Date:  2008-12

Review 8.  Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies.

Authors:  Rozeena Garner; Rakesh Kumari; Peter Lanyon; Michael Doherty; Weiya Zhang
Journal:  BMJ Open       Date:  2015-03-16       Impact factor: 2.692

9.  Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study.

Authors:  Eric Hachulla; Pierre-Yves Hatron; Patrick Carpentier; Christian Agard; Emmanuel Chatelus; Patrick Jego; Luc Mouthon; Viviane Queyrel; Anne-Laure Fauchais; Ulrique Michon-Pasturel; Roland Jaussaud; Alexis Mathian; Brigitte Granel; Elisabeth Diot; Dominique Farge-Bancel; Arsène Mekinian; Jérôme Avouac; Hélène Desmurs-Clavel; Pierre Clerson
Journal:  Ann Rheum Dis       Date:  2015-05-20       Impact factor: 19.103

Review 10.  Raynaud's Phenomenon: A Brief Review of the Underlying Mechanisms.

Authors:  Manal M Fardoun; Joseph Nassif; Khodr Issa; Elias Baydoun; Ali H Eid
Journal:  Front Pharmacol       Date:  2016-11-16       Impact factor: 5.810

View more
  1 in total

1.  Altered ocular microvasculature in patients with systemic sclerosis and very early disease of systemic sclerosis using optical coherence tomography angiography.

Authors:  Nataša Mihailovic; Larissa Lahme; Sonja Braasch; Friederike Rosenberger; Nicole Eter; Jan Ehrchen; Maged Alnawaiseh
Journal:  Sci Rep       Date:  2022-06-29       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.